#United States #Malvern #Endo #ADRENALIN #IV Bags

Endo Expands ADRENALIN® Ready-to-Use Premixed Bag Line

Endo, a fully owned arm of Mallinckrodt plc, has announced an exciting enhancement to its ADRENALIN® product line with the introduction of three new concentrations for its premixed IV bags. These new concentrations—2 mg, 5 mg, and 10 mg of epinephrine per 250 mL—are now available, bringing the total to five concentrations in Endo's portfolio, which also includes 4 mg and 8 mg variants.

The move aims to support healthcare providers by delivering ready-to-use solutions that streamline operations and enhance patient safety, particularly in critical care settings. The 5 mg and 10 mg concentrations are particularly notable as they comply with the American Society of Health-System Pharmacists (ASHP) Standardize 4 Safety Initiative, an effort founded to mitigate medication errors during healthcare operations.

Why ADRENALIN® Matters

ADRENALIN® (epinephrine in 0.9% sodium chloride injection) represents the first FDA-approved, commercially prepared manufacturer premixed epinephrine IV bag, thus paving the way for a more efficient treatment of patients experiencing postoperative hypotension associated with septic shock. This product aligns with the stringent safety protocols now being adopted in medical facilities across the U.S.

Scott Sims, Senior Vice President and General Manager of Endo Injectable Solutions and Generics, emphasized the importance of these innovations, stating, "We strive to empower hospital teams with ready-to-use medications that simplify care processes and enhance patient outcomes."

Key Benefits of the New ADRENALIN® IV Bags

• - No preparation required: Removes the need for nurses or pharmacists to compound or prepare the medication, allowing for faster administration during emergencies.
• - Single-port IV tubing: This design significantly reduces the risks of accidental mixture, enhancing patient safety during administration.
• - Longer shelf life: The new premixed bags have a 24-month shelf life when stored at room temperature, making them a reliable option for emergency departments and critical care units.

With their application primarily focused on increasing mean arterial blood pressure in adult patients suffering from hypotension related to septic shock, these premixed bags stand to revolutionize the approach in acute medical scenarios. They hold promise not just for patient care, but also for optimizing resources and workflow in hospitals.

Addressing Medication Errors

The introduction of these three new concentrations aligns with a broader initiative to standardize medication strengths and dosing across healthcare settings, a movement that is gaining traction. The ASHP’s Standardize 4 Safety Initiative was developed to minimize medication error risks through the implementation of standardized concentration lists. This initiative is particularly crucial in transitional care settings as it helps maintain continuity and consistency in treatment protocols.

Healthcare organizations are encouraged to adopt these new standards to further boost the safety and quality of patient care. With upcoming additional concentration lists from ASHP, awareness and adherence among professionals will continue to grow.

Conclusion

The expansion of the ADRENALIN® line with these new premixed IV bag concentrations is a testament to Endo’s commitment to healthcare excellence. By providing easier access to critical medications while simultaneously mitigating human error, Endo is setting new benchmarks for patient safety within healthcare environments. As hospitals across the nation embrace these updates, the focus remains on what truly matters: enhancing patient outcomes and supporting medical teams in their mission to provide exceptional care.

For more details on these innovations, healthcare professionals can visit ASHP's website.